Incyte Corporation (BMV:INCY)

Mexico flag Mexico · Delayed Price · Currency is MXN
1,180.69
-249.80 (-17.46%)
At close: May 15, 2025
19.75%
Market Cap 244.22B
Revenue (ttm) 90.20B
Net Income (ttm) 434.74M
Shares Out n/a
EPS (ttm) 1.98
PE Ratio 561.76
Forward PE 10.79
Dividend n/a
Ex-Dividend Date n/a
Volume 500
Average Volume 1,481
Open 1,180.69
Previous Close 1,430.49
Day's Range 1,180.69 - 1,180.69
52-Week Range 1,096.52 - 1,486.00
Beta n/a
RSI n/a
Earnings Date Jul 29, 2025

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1991
Employees 2,617
Stock Exchange Mexican Stock Exchange
Ticker Symbol INCY
Full Company Profile

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD Financial Statements

News

There is no news available yet.